Lupin Ltd (LUPIN)
₹2,104.70
Mkt cap
₹96,483 Cr
P/E ratio
16.20
P/B
4.29
Div yield
0.85%
ROE
28.70%
ROCE
29.90%
EPS (TTM)
₹129.92
Book value
₹491
52W range
1,890–2,515
Sector
Healthcare
Price history
Previous close
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
NSE LUPINBSE 500257
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−16.31% from high₹2,105
₹1,890+11.38% from low₹2,515
Current
₹2,104.70
Prev close
₹2,110.00
Day
−0.25%
Price performance
1D
−0.25%
1W
−3.82%
1M
−10.95%
3M
−7.04%
6M
−8.69%
1Y
+10.89%
YTD
−0.03%
Financials
Revenue, profit & margin
P/E ratio
16.2×
LUPIN is 52% below the sector median of 34.0×
LUPIN16.2×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | 8,277 | |
| Expenses | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | 5,827 | |
| Operating Profit | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | 2,450 | |
| OPM % | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% | 32% | 33% | 30% | |
| Other Income | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | -312 | 9 | 130 | |
| Interest | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | 110 | |
| Depreciation | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | 453 | |
| Profit before tax | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | 2,017 | |
| Tax % | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% | 22% | 24% | 30% | |
| Net Profit | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | 1,417 | |
| EPS in Rs | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | 30.95 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.66% · closed higher next day 31 of last 61
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 9 Nov '23 | 7 Feb '24◦ | 7 May '24 | 6 Aug '24◦ | 7 Nov '24◦ | 12 Feb '25 | 14 May '25 | 5 Aug '25◦ | 6 Nov '25◦ | 12 Feb '26◦ | 7 May '26◦ | 6 Aug '26◦ |
| Earnings day | −0.54% | +0.76% | −4.11% | +4.38% | −0.33% | −2.05% | +0.07% | −0.68% | +0.83% | −0.53% | −3.28% | −0.90% |
| +1 day | −2.56% | +1.74% | −3.78% | +7.33% | −1.26% | −0.60% | −0.14% | +4.27% | +1.77% | +0.47% | −8.30% | −3.56% |
| +5 days | −1.22% | +0.68% | −2.53% | +8.54% | −3.59% | −4.32% | −4.96% | +6.72% | +5.10% | +0.38% | −7.48% | −6.29% |
| +15 days | +4.08% | +1.68% | −4.54% | +14.81% | −1.41% | −2.37% | −3.68% | +1.63% | +6.48% | +4.16% | −8.02% | −8.95% |
| +30 days | +5.91% | +0.87% | −6.39% | +13.67% | +2.74% | −1.92% | −6.89% | +10.25% | +8.71% | +2.89% | −4.88% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 18 Per Share | 18.00 | 17 Jul '26 | 17 Jul '26 |
Shareholding
as of Jun 202646.85%Promoter
Promoters46.85%
FIIs22.42%0.72
DIIs24.65%0.67
Public6.08%0.05
Government0.00%
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts86
TranscriptAug 2026PPTAug 2026RECAug 2026PPTAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Press Release / Media Release 4 Sep - Lupin received U.S. FDA approval for Modafinil Tablets USP 100 mg and 200 mg on September 4, 2026.Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015- ESG Rating 28 Aug - Crisil ESG assigned Lupin FY26 ratings of 69 and 65, placing it in the Strong category.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 25 Aug - Intimation of allotment of 30967 equity shares under ESOP.Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - ESG Rating 24 Aug - Independent ESG rating of 60 placed Lupin in Adequate category.Exclusive License Agreement With Visus Therapeutics, Inc. U.S.A. 20 Aug - VISUfarma secures European commercialization rights for YUVEZZI™; deal includes €20 million investment and up to €75 million consideration.